DXCM Chart

1 Month

	Date	Diff	Articles
	2025-05-05	-1.65 %	DexCom (DXCM) stock fell by 1.65% following mixed financial results, including a slight earnings miss and a downward adjustment of gross margin forecasts despite strong sales and a new share buyback program; concerns about the company being overvalued and risks from increasing competition in the diabetes market also contributed to the decline.
DexCom (DXCM) stock fell by 1.65% following mixed financial results, including a slight earnings miss and a downward adjustment of gross margin forecasts despite strong sales and a new share buyback program; concerns about the company being overvalued and risks from increasing competition in the diabetes market also contributed to the decline. DexCom (NASDAQ:DXCM) stock fell 1.65% despite receiving a target price upgrade from Canaccord Genuity because the company reported earnings that missed consensus estimates, with a quarterly EPS of $0.32 compared to the expected $0.33. DexCom (DXCM) stock fell by 1.65% following Piper Sandler's downgrade of its price target from $100.00 to $90.00, despite the company reporting revenue growth; the downgrade likely reflects concerns over recent earnings that fell short of consensus estimates and the performance of the stock amid various analysts' mixed ratings.
	2025-04-29	+0.17 %	DexCom (DXCM) stock rose by 0.17% following expectations of a solid earnings report, with analysts forecasting earnings of $0.33 per share and revenues of $1.02 billion for Q1 2025.
DexCom (DXCM) stock rose by 0.17% following expectations of a solid earnings report, with analysts forecasting earnings of $0.33 per share and revenues of $1.02 billion for Q1 2025. Dexcom (DXCM) stock rose by 0.17% ahead of its upcoming earnings report, which historically tends to cause significant volatility due to investor sentiment and market reactions to earnings announcements. The stock's rise may be attributed to positive earnings expectations, with forecasted earnings per share of $0.33 on revenues of $1.02 billion, indicating potential growth compared to the previous year's performance.
	2025-04-28	-0.67 %	DexCom Inc. (NASDAQ: DXCM) experienced a 0.67% decline last night, amidst a recent positive short-term trend but a significant 44.07% drop over the past year, possibly reflecting concerns about its long-term performance despite recent gains.
DexCom Inc. (NASDAQ: DXCM) experienced a 0.67% decline last night, amidst a recent positive short-term trend but a significant 44.07% drop over the past year, possibly reflecting concerns about its long-term performance despite recent gains.
	2025-04-22	+0.33 %	DexCom (NASDAQ: DXCM) stock rose by 0.33% amid an ongoing investigation by Johnson Fistel, PLLP into potential breaches of fiduciary duties and misleading statements made by the company's insiders. The stock's increase may be attributed to speculation that the investigation could lead to accountability and corrective measures that might stabilize investor confidence following its significant previous decline.
DexCom (NASDAQ: DXCM) stock rose by 0.33% amid an ongoing investigation by Johnson Fistel, PLLP into potential breaches of fiduciary duties and misleading statements made by the company's insiders. The stock's increase may be attributed to speculation that the investigation could lead to accountability and corrective measures that might stabilize investor confidence following its significant previous decline.
	2025-04-21	-3.59 %	Shares of DexCom, Inc. (NASDAQ:DXCM) fell by 3.59% due to a combination of insider selling activity, where executives sold significant portions of their stock, and a quarterly earnings report that missed analysts’ expectations, indicating potential underlying challenges for the company.
Shares of DexCom, Inc. (NASDAQ:DXCM) fell by 3.59% due to a combination of insider selling activity, where executives sold significant portions of their stock, and a quarterly earnings report that missed analysts’ expectations, indicating potential underlying challenges for the company.